Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Enfermedad de Parkinson

2601 ARTíCULOS , VIENDO DEL 91 AL 105

PUBMED

Frequency-dependent neural activity in Parkinson's disease.

Hou Y, Wu X, Hallett M, Chan P, Wu T.

Hum Brain Mapp. 2014 Dec;35(12):5815-33. doi: 10.1002/hbm.22587.

0

0

0

PUBMED

New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.

Hölscher C.

Neural Regen Res. 2014 Nov 1;9(21):1870-3. doi: 10.4103/1673-5374.145342. Review.

0

0

0

PUBMED

Pallidal stimulation in Parkinson's disease does not induce apathy.

Lozachmeur C, Drapier S, Robert G, Dondaine T, Laviolle B, Sauleau P, Peron J, Le Jeune F, Travers D, Millet B, Vérin M, Drapier D.

J Neuropsychiatry Clin Neurosci. 2014 Summer;26(3):221-6. doi: 10.1176/appi.neuropsych.13020032.

0

0

0

PUBMED

[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].

Salvado M, Hernández-Vara J.

Med Clin (Barc). 2014 Feb 20;142(4):186. doi: 10.1016/j.medcli.2013.06.022. Spanish. No abstract available.

0

0

0

PUBMED

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E.

Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4.

0

0

0

PUBMED

A review of the use of magnetic resonance imaging in Parkinson's disease.

Pyatigorskaya N, Gallea C, Garcia-Lorenzo D, Vidailhet M, Lehericy S.

Ther Adv Neurol Disord. 2014 Jul;7(4):206-20. doi: 10.1177/1756285613511507. Review.

0

0

0

PUBMED

Biotherapies for Parkinson disease.

Remy P.

Rev Neurol (Paris). 2014 Dec;170(12):763-9. doi: 10.1016/j.neurol.2014.10.002. Review.

0

0

0

PUBMED

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.

Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, Kordower JH.

Mov Disord. 2014 Jul;29(8):999-1009. doi: 10.1002/mds.25736.

0

0

0

PUBMED

[Key elements for patients and caregivers in the process of living with Parkinson's disease].

Zaragoza Salcedo A, Senosiain García JM, Riverol Fernández M, Anaut Bravo S, Díaz de Cerio Ayesa S, Ursúa Sesma ME, Portillo MC.

An Sist Sanit Navar. 2014 Jan-Apr;37(1):69-80. Spanish.

0

0

0

PUBMED

Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome.

Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F, Tesei S, Meucci N, Mariani CB, Sacilotto G, Zini M, Ruffmann C, Pezzoli G.

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):311-8. doi: 10.1136/jnnp-2012-303988.

0

0

0

PUBMED

Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Kadoguchi N, Okabe S, Yamamura Y, Shono M, Fukano T, Tanabe A, Yokoyama H, Kasahara J.

BMC Neurosci. 2014 Jun 25;15:79. doi: 10.1186/1471-2202-15-79.

0

0

0

PUBMED

In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody.

Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, Liepelt-Scarfone I, Schulte C, Reusch D, Schleicher E, Rothfuss O, Schneider A, Dodel R, Gasser T, Berg D.

Acta Neuropathol. 2014 Dec;128(6):893-5. doi: 10.1007/s00401-014-1364-1. No abstract available.

0

0

0

PUBMED

Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Liu R, Baird D, Park Y, Freedman ND, Huang X, Hollenbeck A, Blair A, Chen H.

Mov Disord. 2014 Jun;29(7):889-96. doi: 10.1002/mds.25771.

0

0

0

PUBMED

Hypersexuality after bilateral deep brain stimulation of the subthalamic nucleus for Parkinson's disease.

Akakin A, Yilmaz B, Urgun K, Ekşi MS, Afşar N, Kiliç T.

Neurol India. 2014 Mar-Apr;62(2):233-4. doi: 10.4103/0028-3886.132453. No abstract available.

0

0

0

PUBMED

Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.

Brichta L, Greengard P.

Front Neuroanat. 2014 Dec 15;8:152. doi: 10.3389/fnana.2014.00152. Review.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy